111 related articles for article (PubMed ID: 11095964)
1. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma.
Tsukuda K; Tanino M; Soga H; Shimizu N; Shimizu K
Biochem Biophys Res Commun; 2000 Nov; 278(3):653-8. PubMed ID: 11095964
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel oncogenic K-ras mutation in colon cancer.
Akagi K; Uchibori R; Yamaguchi K; Kurosawa K; Tanaka Y; Kozu T
Biochem Biophys Res Commun; 2007 Jan; 352(3):728-32. PubMed ID: 17150185
[TBL] [Abstract][Full Text] [Related]
3. [Study of growth inhibition of lung cancer cells by siRNA targeting mutant K-ras gene in vitro and in vivo].
Zhang ZP; Jiang GC; Yang F; Zhou ZL; Wang J
Zhonghua Wai Ke Za Zhi; 2007 Sep; 45(18):1267-70. PubMed ID: 18067742
[TBL] [Abstract][Full Text] [Related]
4. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
[TBL] [Abstract][Full Text] [Related]
5. [Carcinogenesis and its mechanism of mutant-type[12Asp]K-ras4B gene].
Gui LM; Wei LH; Zhang YM; Wang JL; Wang Y; Chen Y; Ma DL
Ai Zheng; 2002 Jan; 21(1):33-8. PubMed ID: 12500394
[TBL] [Abstract][Full Text] [Related]
6. Activation of the K-ras gene by insertion mutations in chemically induced rat renal mesenchymal tumors.
Higinbotham KG; Rice JM; Buzard GS; Perantoni AO
Oncogene; 1994 Sep; 9(9):2455-9. PubMed ID: 8058308
[TBL] [Abstract][Full Text] [Related]
7. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line.
Tokunaga T; Tsuchida T; Kijima H; Okamoto K; Oshika Y; Sawa N; Ohnishi Y; Yamazaki H; Miura S; Ueyama Y; Nakamura M
Br J Cancer; 2000 Sep; 83(6):833-9. PubMed ID: 10952790
[TBL] [Abstract][Full Text] [Related]
8. Stability of ras oncogene mutation in the human tumor xenografts through serial passages.
Kijima H; Abe Y; Yamazaki H; Ohnishi Y; Ueyama Y; Tamaoki N; Nakamura M
Anticancer Res; 1994; 14(6B):2583-7. PubMed ID: 7872685
[TBL] [Abstract][Full Text] [Related]
9. Transfection of K-rasAsp12 cDNA markedly elevates IL-1beta- and lipopolysaccharide-mediated inducible nitric oxide synthase expression in rat intestinal epithelial cells.
Takahashi M; Mutoh M; Shoji Y; Kamanaka Y; Naka M; Maruyama T; Sugimura T; Wakabayashi K
Oncogene; 2003 Oct; 22(48):7667-76. PubMed ID: 14576830
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
Zhang YA; Nemunaitis J; Scanlon KJ; Tong AW
Gene Ther; 2000 Dec; 7(23):2041-50. PubMed ID: 11175317
[TBL] [Abstract][Full Text] [Related]
12. Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation.
Kato K; Ueoka Y; Kato K; Hachiya T; Nishida J; Wake N
Oncogene; 1997 Dec; 15(25):3037-46. PubMed ID: 9444952
[TBL] [Abstract][Full Text] [Related]
13. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
[TBL] [Abstract][Full Text] [Related]
14. [Transformation of NIH/3T3 cells and SW 480 cells displaying K-ras mutation].
Anker P; Lyautey J; Lefort F; Lederrey C; Stroun M
C R Acad Sci III; 1994 Oct; 317(10):869-74. PubMed ID: 7882132
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
[TBL] [Abstract][Full Text] [Related]
16. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12.
Céspedes MV; Sancho FJ; Guerrero S; Parreño M; Casanova I; Pavón MA; Marcuello E; Trias M; Cascante M; Capellà G; Mangues R
Carcinogenesis; 2006 Nov; 27(11):2190-200. PubMed ID: 16679305
[TBL] [Abstract][Full Text] [Related]
17. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
18. Mutated Atf4 suppresses c-Ha-ras oncogene transcript levels and cellular transformation in NIH3T3 fibroblasts.
Mielnicki LM; Hughes RG; Chevray PM; Pruitt SC
Biochem Biophys Res Commun; 1996 Nov; 228(2):586-95. PubMed ID: 8920955
[TBL] [Abstract][Full Text] [Related]
19. [The mouse ovarian surface epithelium cells (MOSE) transformation induced by c-myc/K-ras in].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):881-5. PubMed ID: 17533735
[TBL] [Abstract][Full Text] [Related]
20. [Activation of K-ras and c-erbB-2 protooncogenes in human colonic adenocarcinomas].
Golijow C; Güerci A; Mourón S; Abba M; Dulout FN; Ottino A; Pianzola H
Acta Gastroenterol Latinoam; 2001 May; 31(2):71-6. PubMed ID: 11471321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
